View all news

European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy

08/27/2024

Multimedia Files:

View all news
Questions? Please contact us:
1-800-950-5089 investor-relations@its.jnj.com